Puromycin (CL13900) 2HCl

Catalog No.S7417

For research use only.

Puromycin 2HCl (CL13900) is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.

Puromycin (CL13900) 2HCl Chemical Structure

CAS No. 58-58-2

Selleck's Puromycin (CL13900) 2HCl has been cited by 86 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Other Antineoplastic and Immunosuppressive Antibiotics Products

Biological Activity

Description Puromycin 2HCl (CL13900) is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.
In vitro

The antibiotic puromycin is produced by the actinoniycete, Streptornyces alboniger, and has been used as a tool for studying protein synthesis in a number of systems. [1] Puromycin can be used for the selection of recombinant cells from noncultured cells. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K562 Mn3GS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MknIO|IhcA>? NXy0RlRZT3Kxd4ToJIlvcGmkaYTpc44hd2ZiZH;4c5J2[mmlaX6tdoV{cXO2YX70JIh2dWGwIFu1OlIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OD1{Nj64N{DPxE1w NU\sTlVZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizNVM{ODdpPkG4N|E{OzB5PD;hQi=>
HepG2 MkTtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHq2R|U4OiCq NF\i[3pIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJ\XCJMjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOjNizszNMi=> NFXFV3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOxN|MxPyd-MUizNVM{ODd:L3G+
K562 NUPMbWlIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYm3NkBp NGCzbJZIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBMPTZ{IHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4zOiEQvF2u MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDNzM{OwO{c,OTh|MUOzNFc9N2F-
HepG2 MoPtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGTMWmM4OiCq NV3GU2t[T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjJzIN88UU4> NVrPR45sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1NVI6QDRpPkG4OVEzQTh2PD;hQi=>
Huh7 NHL4W5dEgXSxdH;4bYNqfHliYYPzZZk> NG[zO2dPV1[DUmTJV|ohS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hcGWyYYTvZ4VtdHWuYYKgZ4Fz[2mwb33hJINmdGxibHnu[UApUHWqNzmsJGNEPTB;Nj62N{DPxE1w MojmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3N{m3PFMoRjF6NUe5O|g{RC:jPh?=
HEK239 NHH1bZJEgXSxdH;4bYNqfHliYYPzZZk> M1LheVczKGh? NVv2OpR1S3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlM6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDBcIFu[XJiYnz1[UBie3OjeTygTWM2OD1yLkSyJO69VS5? M3\tblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUW4NFYxLz5{MEW1PFA3ODxxYU6=
J774A1 M{f2XGN6fG:2b4jpZ4l1gSCjc4PhfS=> MniwR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgTlc4PEFzIHPlcIx{KGK7IITyfZBidiCkbIXlJIV5[2y3c3nvckBie3OjeTygTWM2OD1zMDFOwG0v NYnmZlJHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5N|Q3OzZpPkKyPVM1PjN4PD;hQi=>
KB3-1 MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFz2dWc4OiCqcoO= Mmn6S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gT2I{NTFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOjFizszNMi=> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDNzM{OwO{c,OTh|MUOzNFc9N2F-
HepG2/Dox M13hV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFK5T2Q4OiCqcoO= MVfHdo94fGhiaX7obYJqfGmxbjDv[kBufWy2aXTyeYchemW|aYP0ZY51KGi3bXHuJGhmeEd{L1TvfEBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR|UxKD1iMkCuNkDPxE1w MmnEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3MUK5PFQoRjF6NUGyPVg1RC:jPh?=
HEK293 MWXDfZRwfG:6aXPpeJkh[XO|YYm= MonBO|IhcHK| MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KHKnc3H6eZJqdi2kYYPl[EBxdGG2ZTDy[YFl\XJiYX7hcJl{cXNuIFnDOVAhRSByLkO2NUDPxE1w NHjWbmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NVU{Pyd-Mk[2OVE2Ozd:L3G+
HEK293 MofNR5l1d3SxeHnjbZR6KGG|c3H5 MoK4O|IhcHK| NWT1fZJQS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjN3MEWg{txONg>? M4H2VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO|Y{Lz5{N{C2NFc3OzxxYU6=
A549 MVPDfZRwfG:6aXPpeJkh[XO|YYm= M2\2WmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMtKEmFNUCgQUAxNjZizszNMi=> NHzuT2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C4PVIyPCd-MkewPFkzOTR:L3G+
PC3 MULDfZRwfG:6aXPpeJkh[XO|YYm= MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOsJGlEPTBiPTCwMlch|ryPLh?= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB6OUKxOEc,OjdyOEmyNVQ9N2F-
HEK293 MnrvR5l1d3SxeHnjbZR6KGG|c3H5 NUW4dXVbS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hOC5yMECzOUDPxE1w MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzJzMkC3NEc,Ojd{MUKwO|A9N2F-
HEK293 Mo\qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVPwSWNkPzJiaILz MnXnS5Jwf3SqIHnubIljcXSrb36gc4YhUEWNMkmzJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCScnXzeI9DdHWnIIP0ZYlvcW6pIHLhd4VlKG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwM{[g{txONg>? M{jWN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MECxNFY4Lz5{OECwNVA3PzxxYU6=
HEK293 Mk[wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3PDRWdzd3e2aDDpcohq[mm2aX;uJI9nKEiHS{K5N{Bk\WyuczygTWM2OCB;IECuN|k6KM7:TT6= NHfZSVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESwNFI{OSd-Mki0NFAzOzF:L3G+
SU-DHL10 MmXMR5l1d3SxeHnjbZR6KGG|c3H5 MWO3NkBpenN? M{\hXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNWNUSKTEGwJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2cnWtS4xwKGy3bXnu[ZNk\W62IHHzd4F6NCCFQ{WwJF0hOC5zMTFOwG0v MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV{M{GwN{c,Ojh3MkOxNFM9N2F-
MIAPaCa2 MmrtR5l1d3SxeHnjbZR6KGG|c3H5 NHflOXM4OiCqcoO= NF;ZNYNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOUUGSYVPhNkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdILlMWdtdyCudX3pcoV{[2WwdDDhd5NigSxiQ1O1NEA:KDBwMjFOwG0v NFnad|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEWyN|ExOyd-Mki1NlMyODN:L3G+
MDA-MB-231 NUj0SmRMS3m2b4TvfIlkcXS7IHHzd4F6 MUW3NkBpenN? NXHTNpp1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBie3OjeTygR2M2OCB;IECuOFgh|ryPLh?= M4HnW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUKzNVA{Lz5{OEWyN|ExOzxxYU6=
HEK293 MlW0R5l1d3SxeHnjbZR6KGG|c3H5 M3nqdFczKGi{cx?= NHO0dWREgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSByLkS2JO69VS5? M2riTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{e0OFI4Lz5{OEe3OFQzPzxxYU6=
HL60 MXTBcpRqeGG{YYPpeIlkKGG|c3H5 NELReoY4OiCqcoO= NWnSN|I6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGVEPTBiPTCwMlA2PSEQvF2u MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDhyM{C0O{c,Ojh6MEOwOFc9N2F-
MOLT4 NVrIO3R7SW62aYDhdoF{cXSrYzDhd5NigQ>? NEHHb3Q4OiCqcoO= Mn\WRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPT1zUOEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDFR|UxKD1iMD6xO{DPxE1w M{\OelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OECzNFQ4Lz5{OEiwN|A1PzxxYU6=
Vero M4LtbGN6fG:2b4jpZ4l1gSCjc4PhfS=> NYnreIR[PzJiaILz NI\2d|FEgXSxdH;4bYNqfHliYXfhbY5{fCCDZoLpZ4FvKGe{ZXXuJI1wdmuneTDW[ZJwKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygR2M2OCB;IEKuPEDPxE1w NVzSSFJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4NFMxPDdpPkK4PFA{ODR5PD;hQi=>
HEK293 MWDDfZRwfG:6aXPpeJkh[XO|YYm= NHzmN2c4OiCqcoO= NYC3cY5SS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDy[ZNignW{aX6g[JlmKGKjc3XkJIF{e2G7LDDJR|UxKD1iMD60OUDPxE1w NHvLR5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKzOlQ6Oid-MkmyN|Y1QTJ:L3G+
HEK293T MlzMR5l1d3SxeHnjbZR6KGG|c3H5 MUW3NkBpenN? NXXGNGlJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEWNMkmzWEBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyC{ZXHn[Y51KGKjc3XkJIx2dWmwZYPj[Y5k\SCjc4PhfUwhS0N3MDC9JFAvPDJizszNMi=> M3XSclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[5OVc2Lz5{OUS2PVU4PTxxYU6=
HCT8 NF;0dJlCdnSrcHHyZZNqfGmlIHHzd4F6 MljVOFghcHK| MmjtRY51cXCjcnHzbZRq[yCjY4Tpeol1gSCjZ3HpcpN1KEO{eYD0c5Nxd3KrZHn1cUBx[XK4dX2gRmdHKGmwZnXjeIVlKGmwIHj1cYFvKEiFVEigZ4VtdHNiaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhTkmWQz;ERXBKKHO2YXnubY5oKGKjc3XkJIZtfW:{ZYPj[Y5k\SCjc4PhfUwhTUN3MDC9JFAvPTVizszNMi=> NE\Ed2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2PVU4PSd-Mkm0Olk2PzV:L3G+
HCT8 MknERY51cXCjcnHzbZRq[yCjc4PhfS=> MnXoOFghcHK| NXfiXYhRSW62aYDhdoF{cXSrYzDhZ5Rqfmm2eTDh[4FqdnO2IFPyfZB1d3Oyb4Lp[Il2dSCyYYL2eY0hW1COIHnu[oVkfGWmIHnuJIh2dWGwIFjDWFgh[2WubIOgbY5kfWKjdHXkJIZweiB2ODDodpMh[nliRlnUR{9FSVCLIIP0ZYlvcW6pIHLhd4VlKG[udX;y[ZNk\W6lZTDhd5NigSxiRVO1NEA:KDBwNjFOwG0v MmPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nkm1O|UoRjJ7NE[5OVc2RC:jPh?=
HepG2 NHfleppEgXSxdH;4bYNqfHliYYPzZZk> NGPnPVg4OiCqcoO= M1;n[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJJJm[WenboSgZoF{\WRibIXtbY5me2OnbnPlJIF{e2G7LDDDR|UxKD1iMD64N{DPxE1w NV62colMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0Olk2PzVpPkK5OFY6PTd3PD;hQi=>
HCT8 M2nOXWN6fG:2b4jpZ4l1gSCjc4PhfS=> M4\uPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDhiY3XscJMtKEWFNUCgQUA3NjFizszNMi=> NFS1WIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2PVU4PSd-Mkm0Olk2PzV:L3G+
HEK293 NEDQdpREgXSxdH;4bYNqfHliYYPzZZk> NELXTGY4OiCqcoO= NGfzN5JEgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmsJGlEPTBiPTCwMlQ3KM7:TT6= MorzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{O2NVEoRjJ7NUOzOlEyRC:jPh?=
HEK293 M1jpdmN6fG:2b4jpZ4l1gSCjc4PhfS=> M2f4XlczKGi{cx?= NEK4N3pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJTUt{OUOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHKnc3H6eZJqdiCmeXWgZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7LDDJR|UxKD1iMD60JO69VS5? MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl4OUK2Nkc,Ojl7NkmyOlI9N2F-
A549 NFHZR3FEgXSxdH;4bYNqfHliYYPzZZk> M2DGTVQ5KGi{cx?= M3rlXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzMEBKSzVyIE2gNE4{KM7:TT6= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODRzOEe2N{c,OzB2MUi3OlM9N2F-
PC3 NUPjU3VES3m2b4TvfIlkcXS7IHHzd4F6 NUe2UI1nPDhiaILz MlXtR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czygTWM2OCB;IECuN{DPxE1w MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODRzOEe2N{c,OzB2MUi3OlM9N2F-
Assay
Methods Test Index PMID
Western blot Cyclin D1 / CDK4 ; PARP / Bcl-xL / Bcl-2 / p-Akt / Akt ; p53 / p21 / c-Myc 31022952
Growth inhibition assay Cell viability 31022952

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 100 mg/mL warmed
(183.67 mM)
Water 100 mg/mL warmed
(183.67 mM)
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 544.43
Formula

C22H29N7O5.2HCl

CAS No. 58-58-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CN(C)C1=NC=NC2=C1N=CN2C3C(C(C(O3)CO)NC(=O)C(CC4=CC=C(C=C4)OC)N)O.Cl.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Puromycin (CL13900) 2HCl | Puromycin (CL13900) 2HCl supplier | purchase Puromycin (CL13900) 2HCl | Puromycin (CL13900) 2HCl cost | Puromycin (CL13900) 2HCl manufacturer | order Puromycin (CL13900) 2HCl | Puromycin (CL13900) 2HCl distributor